Investment case
Novartis AG
NVS · 16 developments mapped · last assessed 2026-09-24
Market Ontology has mapped 16 macro, policy, and market developments to Novartis AG since 2026-09-01. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for NVS yet, so no modelled value is shown. The NVS valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run NVS on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Novartis Remibrutinib Meets Primary Endpoint in Phase III MS Trial
Successful Phase III trial for a novel drug in a significant market (MS) increases future revenue potential and strengthens pipeline. Reduces R&D risk.
· Moves probability of success for pipeline assets, peak sales estimates for remibrutinib, discount rate (due to reduced risk)
- Main threat
Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint
Direct R&D failure, loss of potential future revenue stream from a key pipeline asset.
· Moves probability of success for pipeline assets, peak sales estimates for pelacarsen, discount rate reflecting r&d risk
- Open question
FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA
Increased competition in the Spinal Muscular Atrophy (SMA) market. Similar to Biogen, Novartis's SMA treatment may face altered market dynamics due to a new combination therapy option.
· Moves market share for zolgensma (sma gene therapy), pricing power in the sma market
What changed, by assumption
- 2026-09-01Novartis Remibrutinib Meets Primary Endpoint in Phase III MS Trial
- 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint
- 2026-09-01Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS Trials
- 2026-09-05Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500M
- 2026-09-05Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpoint
- 2026-09-16CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth
- 2026-09-14FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
- 2026-09-12FDA Approves Isembyld for Spinal Muscular Atrophy
- 2026-09-12FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy
- 2026-09-12FDA approves Scholar Rock's Isembyld for spinal muscular atrophy
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-24 | Kyverna Therapeutics Reports Positive One-Year Data for Miv-cel; Rolling BLA Submission on Track for Q4 2026 | watch | 3-12m | 0.20 |
| 2026-09-16 | CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth | Bullish | 1-5y | 0.60 |
| 2026-09-14 | FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy | Bearish | 3-12m | 0.50 |
| 2026-09-14 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA | mixed | 3-12m | 0.30 |
| 2026-09-13 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted SMA Therapy | mixed | 3-12m | 0.30 |
| 2026-09-13 | FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy | watch | 3-12m | 0.30 |
| 2026-09-12 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA | watch | 3-12m | 0.30 |
| 2026-09-12 | FDA Approves Isembyld for Spinal Muscular Atrophy | Bearish | 1-3m | 0.40 |
| 2026-09-12 | FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy | Bearish | 1-3m | 0.40 |
| 2026-09-12 | FDA approves Scholar Rock's Isembyld for spinal muscular atrophy | mixed | 3-12m | 0.30 |
| 2026-09-05 | Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint | Bearish | 1-3m | 0.80 |
| 2026-09-05 | Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500M | Bearish | 1-3m | 0.70 |